Thalidomide, Cyclophosphamide, Oral Idarubicin and Dexamethasone (T-CID) in Patients With Multiple Myeloma
Status:
Unknown status
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
Background: In some studies, thalidomide in combination with chemotherapy has been shown to
be effective in patients with relapsed or refractory multiple myeloma (MM). In this study,
the researchers have chosen a regimen which can be administered on an outpatient basis.
Induction therapy: To evaluate the efficacy and toxicity of thalidomide, cyclophosphamide,
oral idarubicin and dexamethasone (T-CID) in patients with relapsed or refractory multiple
myeloma.
Maintenance therapy: Randomized trial to compare efficacy and toxicity of thalidomide and
thalidomide plus oral idarubicin as maintenance therapy in patients with at least stable
disease after T-CID.